{"disease":{"id":"preventive-treatment-of-episodic-migraine","name":"Preventive treatment of episodic migraine","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[{"drug_id":"atogepant","indication_name":"Preventive treatment of episodic migraine in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qulipta","generic_name":"ATOGEPANT","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Calcitonin gene-related peptide type 1 receptor","drug_class":"Calcitonin Gene-related Peptide Receptor Antagonist [EPC]","quality_score":66,"revenue":"201","mechanism":"Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain."},{"drug_id":"fremanezumab-vfrm","indication_name":"Preventive treatment of episodic migraine in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fremanezumab-Vfrm","company_name":"Manhattan Beach Orthodontics","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide (CGRP)","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Fremanezumab-vfrm binds to CGRP and blocks its interaction with the receptor."}],"pipeline":[{"drug_id":"rimegepant-75-mg","indication_name":"Preventive treatment of episodic migraine","indication_type":"pipeline","phase":"Phase 4","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":2,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"nurtec-odt","guideline_body":"FDA label","recommendation":"NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"rimegepant","guideline_body":"FDA label","recommendation":"NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}